Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-8765
Fax+1 214-645-8769
Dr. Woldu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Solomon Woldu is an urologist in Dallas, TX and is affiliated with multiple hospitals in the area, including William P. Clements, Jr. University Hospital, Parkland Health & Hospital System, JPS Health Network, and Veterans Affairs North Texas Health Care System. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 7 years. He specializes in surgical oncology and is experienced in urology and urologic neoplasms.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2016 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 2011 - 2016- New York Presbyterian HospitalInternship, Transitional Year, 2010 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2010
Washington University in St. LouisB.A., Biology, 2002 - 2006
Certifications & Licensure
TX State Medical License 2016 - 2025
American Board of Urology Urology
Clinical Trials
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer Start of enrollment: 2021 Sep 06
- Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma Start of enrollment: 2021 Nov 29
Publications & Presentations
PubMed
- Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis.Zine-Eddine Khene, Raj Bhanvadia, Isamu Tachibana, Wadih Issa, William Graber
Clinical Genitourinary Cancer. 2025-04-01 - Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive N...Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, Zine-Eddine Khene, Jeffrey Howard
European Urology Oncology. 2025-04-01 - Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities.Raj R Bhanvadia, Rohit R Badia, Fady J Baky, Jennifer W Tse, Yair Lotan
Canadian Urological Association Journal = Journal De L'association Des Urologues Du Canada. 2025-03-17
Authored Content
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Press Mentions
Upper Urinary Tract Cancer Drug May Offer Long-Term BenefitsMarch 10th, 2025- Socioeconomic Factors Linked to Immunotherapy Use in Urologic CancersSeptember 10th, 2024
- Socioeconomic Disparities Impact Immunotherapy Use in Urologic CancersSeptember 9th, 2024
- Join now to see all
Grant Support
- T32 GrantNational Institute of Health2016–2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
